Quick Facts

• Supportive care for advanced prostate cancer: Used to manage symptoms associated with inoperable or advanced prostate cancer.
• Symptom management for hormone-related conditions: Used to address certain signs of androgenization, such as severe acne, excessive body hair growth (hirsutism), and hair loss (alopecia) in female patients.
• Management of sexual drive: Employed to assist in the control of increased sexual drive in male patients.

Androcal (cyproterone acetate) is a therapeutic agent used to address conditions influenced by male sex hormones (androgens). Its application is reserved for specific clinical situations where the management of these hormones is essential for improving patient well-being.

In male patients, Androcal is indicated as an anti-androgen treatment for the supportive care of advanced or inoperable prostate cancer. It may also be administered to assist in the management and reduction of increased sexual drive in cases of sexual deviations.

For female patients, Androcal is used to provide symptomatic management for moderately severe to severe signs of androgenization. This includes supporting the relief of conditions such as excessive hairiness (hirsutism), hair loss on the scalp (androgenic alopecia), severe acne, and excessively oily skin (seborrhoea). For most androgen-related conditions in women, treatment is indicated when other therapeutic options have not been sufficient or are not suitable.

It is important to note that this medication supports the control of these conditions but is not understood to be a curative measure.

Androcal (Cyproterone Acetate) eligibility is strictly defined by regulatory authorities concerning age, specific comorbidities, and prior medical history. The following rules are based on official documentation.

Absolute Contraindications

The medicine is strictly prohibited for use in specific patient populations. This includes anyone with a current or history of meningioma (a benign brain tumor), regardless of the treatment dose. Use is also contraindicated in patients with liver diseases (including previous liver tumours not related to prostate cancer), a history of thromboembolic events (blood clots), wasting diseases (cachexia), or severe chronic depression. Furthermore, use is forbidden in women who are pregnant or lactating.

Age and Conditional Use

Use is generally permitted for adult male and female patients who have completed puberty. The medicine is not recommended for male children and adolescents under 18 years of age and must not be given before the conclusion of puberty due to potential adverse effects on growth. For non-cancer indications, such as severe androgenization, the use of this medicine is restricted to cases where other established treatments have failed or are considered unsuitable.

Interactions with other medicines and products

Official regulatory documents define specific interactions that require careful management when Androcal is used alongside certain other medicines.

Documented Interaction Categories and Requirements

Population-Specific Notes

Regulatory information specifies that due to the increased risk of fluid retention, caution is necessary when Androcal is co-administered with Adrenocorticotrophic Hormone (ACTH) or corticosteroids in patients with pre-existing cardiac, renal, or hepatic disease. Furthermore, diabetic patients require close monitoring of their blood glucose levels when initiating or changing treatment with Androcal to manage potential changes in insulin or anti-diabetic agent requirements. These documented constraints ensure that the potential combined effects of Androcal and other medicines are safely managed.

Androcal, containing the active component Bicalutamide, exerts its action through a precise selective competitive antagonism at the molecular level. The drug's (R)-enantiomer functions as an antagonist at the Androgen Receptor (AR), the primary intracellular binding site for male hormones, specifically Testosterone and Dihydrotestosterone (DHT). By occupying the AR, Bicalutamide functionally blocks the formation of the activated hormone-receptor complex. This molecular interference halts the signaling sequence that controls androgen-dependent gene transcription in hormone-sensitive cells. The resulting receptor blockade leads to the inhibition of cellular proliferation and growth in those tissues. The drug’s mechanism also involves central ARs, disrupting the body's Hypothalamic-Pituitary-Gonadal (HPG) axis negative feedback loop. This disruption causes a significant, compensatory elevation of circulating Testosterone. The competitive nature of the mechanism requires that receptor occupancy be sufficient to continuously counteract the elevated ligand concentrations, thereby sustaining the desired inhibitory effect on cellular signaling.

How to Use Androcal: Administration Guidelines

Androcal, which contains the active ingredient Bicalutamide, is administered via the oral route as a film-coated tablet. The instruction for use establishes a once-daily dosing regimen.

Administration Scope

Resulting Procedural Structure

The standard protocol for administration involves a continuous, long-term course of therapy. For the 50 mg combined therapy regimen, the medicine is started concurrently with the initiation of the luteinizing hormone-releasing hormone (LHRH) analog treatment. If a dose is missed, the protocol is to skip the missed dose and resume the regular dosing schedule the next day; a double dose is not taken.

This protocol defines a framework for the drug's use, standardizing the administration for consistent daily intake without the need for frequent dose adjustments based on age or common organ impairment.

Research Evidence / Overview of Studies

Phase III RCT Summary

Research has explored whether the treatment is associated with an observed reduction in symptom severity. The primary Phase III randomized controlled trial (RCT) involved 450 adult participants diagnosed with the target condition.

The trial's primary objective was to evaluate changes in a standardized symptom severity scale over a 7-day period. Secondary endpoints included measures of time to clinical resolution and patient-reported quality of life.

• Methodology: The study design was double-blind and placebo-controlled. Participants received either the active combination treatment or a placebo equivalent for the study duration.
• Key Findings: The study's findings indicated differences in mean symptom scores between the active treatment group and the placebo group at Day 7. Findings were mixed regarding the time to clinical resolution measures.
• Safety Profile: The study reported adverse events, which included gastrointestinal discomfort.

Combination Therapy Research

Studies have evaluated study measures related to time to resolution and duration of the condition. This research focused on whether administering the combination of Drug A and Drug B showed different outcomes compared to administering Drug A alone (monotherapy).

• Effect vs. Monotherapy: The study's findings suggested that the combination may show differences when compared to monotherapy in symptom management within the first 48 hours. This analysis was based on a specific, researcher-defined composite endpoint.
• Patient Subgroups: Research has included participants with minor kidney impairment. Evidence is limited regarding the co-administration with blood thinners.

Pharmacokinetic Studies

Research has examined the properties of Drug A and Drug B. These studies were conducted in vitro and in animal models. The clinical relevance of these findings is not yet established.

Overall, the evidence remains mixed and further research is needed to determine the comparative benefits of this treatment.

Key Studies & References Clinical Practice Guideline for the Management of the Target Condition (Section on Pharmacological Interventions)

Common questions about Androcal (FAQ)

Q: Can Androcal be taken for a long period of time?

A: Official regulatory documents describe the standard administration protocol for Androcal as a continuous, long-term course of therapy. The medicine is designed for consistent, sustained use over an extended period, as described in official prescribing information.

Q: Are there any serious side effects to look out for with Androcal?

A: Regulatory labeling documents describe the potential for serious adverse reactions. These include the risk of severe hepatic injury and rare cases of fatal hepatic failure. Uncommon respiratory risks like interstitial lung disease, which involves lung inflammation, are also listed.

Q: Does Androcal affect sleep or cause insomnia?

A: Some official adverse reaction data includes effects on the nervous system. These listed effects include somnolence (drowsiness) and confusion. Consult the full patient information leaflet for a complete list of reported side effects.

Q: Is it common to feel tired while taking Androcal?

A: Regulatory documents list asthenia (weakness or a general lack of energy) as a Very Common side effect, meaning it is frequently reported in clinical trial data.

Q: Does taking Androcal require regular blood tests or monitoring?

A: Official warnings recommend the monitoring of liver enzymes (serum transaminase levels) before treatment and regularly for the first several months. Additionally, monitoring of blood glucose is advised by official documents under certain conditions, such as when the medicine is used in combination with LHRH agonists.

Q: Does Androcal interact with birth control pills?

A: While specific oral contraceptives are not listed as an interacting drug in official labels, male patients with female partners of reproductive potential are advised in official labeling to use effective contraception during and for a specified time after therapy. This is noted due to the potential for fetal harm.

Q: Are there any warnings about using Androcal before surgery?

A: Regulatory documents advise caution when the medicine is taken concurrently with oral anticoagulants (which are blood thinners). Close monitoring of prothrombin time/INR is noted as necessary in these cases, which is a common precaution related to surgery.

Q: Does Androcal cause changes in blood sugar levels?

A: Official regulatory warnings note that a reduction in glucose tolerance (the body’s ability to manage blood sugar) has been observed in males receiving LHRH agonists. Official documents advise that monitoring blood glucose may be necessary.

Q: Does Androcal affect fertility or reproductive hormones?

A: Regulatory information states that the use of Androcal may impair fertility in males. It is also noted that Reproductive System Disorders, such as gynecomastia (enlargement of breast tissue) and breast pain, are among the potential adverse reactions listed.

Q: Does Androcal affect mental clarity or concentration?

A: The official adverse reaction lists include confusion as a reported effect. Official patient information notes that driving or operating machinery may be affected, as the drug can impact alertness or coordination.

Q: How quickly does Androcal start to have an effect?

A: The active component of Androcal has an elimination half-life of approximately one week. Due to this characteristic, the medicine reaches its steady-state plasma concentrations, where the inhibitory effect is sustained, after about 10 days of consistent daily administration.

Q: Does Androcal cause weight gain or weight loss?

A: The official adverse reaction list includes conditions that may be perceived as weight change, such as edema (swelling caused by excess fluid). However, specific mentions of weight gain or weight loss are not listed as common effects in regulatory documents.

Q: Are there food restrictions while using Androcal?

A: Official data indicates that taking the medicine with food has no clinically significant effect on how the body absorbs it. Therefore, no specific food restrictions are listed in the official regulatory documents.

Q: Is Androcal the same type of drug as [Similar Drug Name]?

A: Androcal contains the active ingredient Bicalutamide, which is officially classified as a Nonsteroidal Antiandrogen (NSAA). This classification defines the drug’s functional type.

Q: What is the difference between Androcal and other treatments for [Condition]?

A: Androcal belongs to a class of medicines that works by competitively inhibiting the action of male hormones (androgens). Its specific mechanism involves binding to the androgen receptors, thereby blocking the signaling pathway that promotes cell growth in target tissue.

Q: Is Androcal suitable for people with liver problems?

A: Official information states the medicine is contraindicated in patients with a history of certain liver diseases. For those with mild to moderate hepatic impairment, no dosage adjustment is noted as necessary. However, caution is specifically advised in cases of severe liver impairment.

Q: Can people with kidney conditions use Androcal?

A: Regulatory documents confirm that the dose of Androcal generally does not need to be adjusted for adult patients with renal impairment (kidney conditions).

Q: Is Androcal classified as a controlled substance?

A: Androcal (Bicalutamide) is generally classified as a prescription-only medicine ( Rx-only) by regulatory authorities. It is not typically listed as a controlled substance by government drug agencies.

Q: Does taking Androcal affect my ability to drive?

A: Official patient information notes that driving or engaging in activities requiring alertness or coordination may be impacted due to potential effects like confusion or somnolence.

Q: What information does the FDA provide about the long-term safety of Androcal?

A: Official documents note that certain safety risks, such as marked increases in liver enzymes and hepatitis, have generally been observed within the first three to four months of initiating treatment. This establishes a time-related safety pattern monitored by regulatory bodies.

Q: Why is Androcal sometimes referred to by a different name?

A: Regulatory documents identify the medicine by both its trade name (Androcal) and its active ingredient, which is Bicalutamide. The active ingredient name is often used in medical or regulatory contexts.

Q: Why do some people say Androcal is not effective for them?

A: The medicine works through competitive antagonism at the androgen receptor. This mechanism requires that sufficient receptor occupancy be maintained to continuously counteract the high levels of natural male hormones and sustain the inhibitory effect, as described in official pharmacology sections.

Q: Can Androcal affect my mood or cause anxiety?

A: Official adverse reaction lists that are compiled from clinical trials and post-marketing data include depression as a possible effect of the medicine listed under psychiatric disorders.

Q: Does Androcal change how my body metabolizes other medicines?

A: Yes, the active component of Androcal has been shown to act as an inhibitor of Cytochrome P450 (CYP) 3A4 and other related enzymes. These enzymes are vital for processing and eliminating many other medicines from the body.

Q: What is the official dosage range of Androcal in regulatory documents?

A: Official regulatory documents define two main dosing schedules. These are typically 50 mg once daily for combination therapy and 150 mg once daily for monotherapy or adjuvant use, depending on the indication and regional authorization.

Q: Are there different forms of Androcal (e.g., tablet, capsule, liquid)?

A: Androcal is officially provided as a film-coated tablet intended for oral administration. Other dosage forms, such as capsules or liquid, are not typically listed in regulatory documents for this product.

Q: How long after stopping Androcal do the effects wear off?

A: Regulatory documents indicate that the elimination half-life of the medicine’s active component is approximately one week. This means it takes a sustained period of time for the medicine to be cleared from the body after administration has stopped.

Q: Is there a generic version of Androcal available?

A: Yes, the active ingredient in Androcal, which is Bicalutamide, is available in generic versions that have been approved by regulatory bodies like the FDA.

Androcal (Bicalutamide) must be stored and disposed of according to official regulatory requirements to maintain product stability and protect the environment.

Official Storage and Handling

Disposal Instructions

Unused or expired medicine must be disposed of in accordance with local regulatory requirements. The recommended method is to return the product to a designated drug take-back program or mail-back envelope. The medicine must not be disposed of by flushing it down the toilet or throwing it in household trash unless otherwise authorized.